| oxaliplatin / Generic mfg. |
NCT00354887: Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater |
|
|
| Completed | 2 | 31 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi-Synthelabo | Gastrointestinal Cancer | 11/09 | 11/09 | | |
NCT00321828: Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 90 | US | bevacizumab, fluorouracil, 5-FU, leucovorin, leucovorin calcium, oxaliplatin | NSABP Foundation Inc, National Cancer Institute (NCI) | Colorectal Cancer | 11/09 | 12/12 | | |
|
|
NCT00448682: Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery |
|
|
| Terminated | 2 | 25 | US | Docetaxel, Taxotere, Floxuridine, 5-fluorodeoxyuridine, 5-FU, FudR, Leucovorin, Folinic acid, Leucovorin calcium, Oxaliplatin | University of Miami | Gastric Cancer | 12/09 | 03/10 | | |
NCT00425841: Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer |
|
|
| Completed | 2 | 29 | Europe | gemcitabine hydrochloride, oxaliplatin, adjuvant therapy, neoadjuvant therapy, hypofractionated radiation therapy, stereotactic radiosurgery | Technische Universität München | Pancreatic Cancer | | 12/09 | | |
NCT00537823: Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement |
|
|
| Terminated | 2 | 9 | US | Cetuximab, Erbitux, Bevacizumab, Avastin, Leucovorin, Oxaliplatin, Fluorouracil | Washington University School of Medicine | Colorectal Cancer, Metastases | 12/09 | 07/11 | | |
NCT00737373 / 2006-006936-24: Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer |
|
|
| Completed | 2 | 143 | Europe | Docetaxel, 5-Fluorouracil, Oxaliplatin, folinic acid | Krankenhaus Nordwest | Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction | 12/09 | 03/11 | | |
| Completed | 2 | 44 | Europe | IMC-11F8 (necitumumab), Necitumumab, IMC-11F8, LY3012211, Portrazza®, Oxaliplatin, Folinic acid (FA), 5-FU | Eli Lilly and Company | Metastatic Colorectal Cancer | 01/10 | 10/10 | | |
NCT00559455: Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Completed | 2 | 38 | RoW | Oxaliplatin, Fluorouracil, Leucovorin | Sanofi | Carcinoma, Hepatocellular | 01/10 | 01/10 | | |
NCT00613080: Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer |
|
|
| Completed | 2 | 79 | Canada, US | capecitabine, oxaliplatin, 50 mg/m^2 IV over 2 hours weekly for five weeks starting on day 1 of radiotherapy., resection, radiation therapy, FOLFOX, Oxaliplatin, leucovorin, 5-fluorouracil | Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology | Colorectal Cancer | 01/10 | 12/16 | | |
NCT00220116: Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer |
|
|
| Completed | 2 | 172 | Europe | Capecitabine, Oxaliplatin | Royal Marsden NHS Foundation Trust | Colorectal Cancer | | | | |
NCT00601198: A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 4 | US | Amifostine, Flurouracil (5-FU), Leucovorin calcium (LV), Oxaliplatin, Bevacizumab | University of Cincinnati, MedImmune LLC, AstraZeneca | Colorectal Cancer | 01/10 | 01/10 | | |
NCT00483405: Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer |
|
|
| Completed | 2 | 33 | US | cetuximab, Erbitux, capecitabine, Xeloda, oxaliplatin, Eloxatin | UNC Lineberger Comprehensive Cancer Center, Sanofi, Roche Pharma AG, Bristol-Myers Squibb, National Center for Research Resources (NCRR), National Cancer Institute (NCI) | Liver Cancer | 02/10 | 12/10 | | |
|
NCT01024504: Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 46 | Europe | Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Bevacizumab, Avastin | Hellenic Oncology Research Group, University Hospital of Crete | Metastatic Colorectal Cancer | 03/10 | 03/10 | | |
NCT00761241: Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT |
|
|
| Completed | 2 | 40 | US | Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy, Pancreaticoduodenectomy | Benaroya Research Institute, Sanofi | Pancreatic Cancer | 03/10 | 04/10 | | |
NCT00448760: Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery |
|
|
| Completed | 2 | 29 | US | Docetaxel, Taxotere, Floxuridine, FUdR, Leucovorin, Oxaliplatin, Microarray analysis, reverse transcriptase-polymerase chain reaction, Conventional surgery | University of Miami | Esophageal Cancer | 04/10 | 04/10 | | |
| Completed | 2 | 275 | US, Europe, RoW | Docetaxel + Oxaliplatin, Docetaxel + Oxaliplatin + 5-FU, Docetaxel + Oxaliplatin + Capecitabine | Sanofi | Stomach Neoplasms | 04/10 | 04/10 | | |
NCT01135498 / 2005-004662-16: A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 90 | Europe | bevacizumab [Avastin], eloxatin, capecitabine [Xeloda], erlotinib [Tarceva] | Hoffmann-La Roche | Colorectal Cancer | 04/10 | 04/10 | | |
| Completed | 2 | 14 | Europe | Mangafodipir, Teslascan; ACT code V08CAE05, Placebo treatment (0.9% NaCl) | Egetis Therapeutics | Chemotherapy, Colon Cancer | 04/10 | 04/10 | | |
| Completed | 2 | 56 | Europe | docetaxel, oxaliplatin, capecitabine, xeloda, taxotere, eloxatin | Martin-Luther-Universität Halle-Wittenberg | Stomach Neoplasms | 05/10 | 01/13 | | |
NCT00588900: Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab |
|
|
| Terminated | 2 | 5 | US | cediranib maleate, irinotecan hydrochloride | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 05/10 | 11/11 | | |
NCT00525005: Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer |
|
|
| Completed | 2 | 44 | RoW | DOS (Docetaxel, Oxaliplatin and S-1), Taxotere, Eloxatin, TS-1 | Hallym University Medical Center, Asan Medical Center, Sanofi | Stomach Neoplasms | 06/10 | 06/10 | | |
NCT00479752: Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 151 | Europe, RoW | FOLFOX4 (Oxaliplatin), Cetuximab | Central European Cooperative Oncology Group | Colorectal Cancer | 06/10 | 11/15 | | |
|
|
NCT01159171 / 2005-001012-41: A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer. |
|
|
| Completed | 2 | 50 | Europe | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 07/10 | 07/10 | | |
NCT00454636 / 2006-004512-43: A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. |
|
|
| Completed | 2 | 158 | Europe | Cisplatin, Capecitabine, Xeloda, Epirubicin, Oxaliplatin, Docetaxel | Hoffmann-La Roche | Gastric Cancer | 07/10 | 07/10 | | |
NCT00421824 / 2005-005149-20: Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer |
|
|
| Completed | 2 | 108 | Europe | Oxaliplatin, capecitabine, Radiotherapy | Sanofi | Rectal Neoplasms | 11/10 | 11/10 | | |
NCT00436241: A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer. |
|
|
| Completed | 2 | 45 | RoW | Oxaliplatin, capecitabine [Xeloda] | Hoffmann-La Roche | Gastric Cancer | 11/10 | 11/10 | | |
NCT00127036: Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) |
|
|
| Terminated | 2 | 65 | US | XELOX, Oxaliplatin and Capecitabine, XELIRI, Irinotecan and Capecitabine, Bevacizumab, Avastin® | H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG | Adenocarcinoma, Colon Cancer | 12/10 | 12/10 | | |
NCT01022541 / 2005-004505-29: Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 47 | Europe | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Liver metastasectomy | Royal Marsden NHS Foundation Trust, Roche Pharma AG | Metastatic Colorectal Cancer | 12/10 | 02/15 | | |
|
|
| Completed | 2 | 30 | Europe | Irinotecan, CPT-11, Campto, Leukovorin, LV, Oxaliplatin, LoHP, Eloxatin, 5-FLUOROURACIL, 5-FU, Cetuximab, Erbitux | University Hospital of Crete | Metastatic Colorectal Cancer | 12/10 | 12/10 | | |
NCT00675012 / 2007-003668-24: NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 24 | Europe | NGR-hTNF, Oxaliplatin, capecitabine | AGC Biologics S.p.A. | Colon Cancer | 12/10 | 05/13 | | |
NCT00636610: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 199 | NA | Vismodegib 150 mg, GDC-0449, Erivedge, Placebo to vismodegib, Bevacizumab, Modified FOLFOX, FOLFIRI | Genentech, Inc. | Metastatic Colorectal Cancer | 12/10 | 12/10 | | |
HEARTO, NCT01348412: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure |
|
|
| Completed | 2 | 31 | Europe | oxaliplatin, raltitrexed, other intravenous chemotherapy drugs | Centre Georges Francois Leclerc, National Cancer Institute, France, Hospira, now a wholly owned subsidiary of Pfizer | Colorectal Cancer, Liver Metastases | 12/10 | 04/18 | | |
NCT00514020: Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 33 | US | fluorouracil, leucovorin calcium, oxaliplatin, gene expression analysis, polymorphism analysis, protein expression analysis, pharmacological study | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Gastric Cancer | 01/11 | 02/11 | | |
NCT00845039: A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab |
|
|
| Terminated | 2 | 4 | US | Cetuximab, Erbitux, LY2939777, Irinotecan, Camptosar, IMC-A12 (cixutumumab), Cixutumumab, LY3012217 | Eli Lilly and Company, NSABP Foundation Inc | Colon Cancer, Rectal Cancer | 02/11 | 02/11 | | |
NCT00881504: A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma |
|
|
| Terminated | 2 | 9 | US | "Bevacizumab" in combination with "modified FOLFOX6"., Avastin, Eloxatin | Georgetown University, Sanofi | Biliary Tract Cancer | 02/11 | 12/11 | | |
NCT00564720: Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer |
|
|
| Terminated | 2 | 140 | Europe | Gemcitabine, Gemzar, Erlotinib, Tarceva, Oxaliplatin, Eloxatin | Hellenic Oncology Research Group, University Hospital of Crete | Pancreatic Cancer | 03/11 | 03/11 | | |
NCT00615056 / 2007-006283-30: A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen |
|
|
| Completed | 2 | 171 | Japan, US, Canada, Europe, RoW | Bevacizumab (avastin), FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]) | Pfizer | Colorectal Neoplasms | 03/11 | 04/12 | | |
|
|
NCT01672333: Response Rate and Side Effects of Preoperative Chemotherapy (TOX Regimen) in Patients With Locally Advanced Operable Gastric Adenocarcinoma |
|
|
| Completed | 2 | 50 | RoW | TOX | Milad Hospital | Gastric Cancer | 03/11 | | | |
APRIORI, NCT01126866: Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy |
|
|
| Terminated | 2 | 35 | Europe | intensified chemotherapy (FOLFOXIRI/Bevacizumab) | National Center for Tumor Diseases, Heidelberg, Roche Pharma AG, Pfizer | Colorectal Carcinoma | 03/11 | 06/11 | | |
| Completed | 2 | 268 | Europe, RoW | aflibercept, ZALTRAP™, AVE0005, oxaliplatin, 5-FU, Folinic Acid | Sanofi | Colorectal Neoplasms, Neoplasm Metastasis | 04/11 | 01/12 | | |
|
| Completed | 2 | 48 | Canada, Europe | IMC-1121B (ramucirumab), ramucirumab, LY3009806, Oxaliplatin, Folinic acid, 5-FU | Eli Lilly and Company | Colorectal Carcinoma | 04/11 | 08/11 | | |
|
NCT00544349: Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery |
|
|
| Completed | 2 | 45 | Europe | cetuximab, fluorouracil, leucovorin calcium, oxaliplatin | Gustave Roussy, Cancer Campus, Grand Paris | Colorectal Cancer, Metastatic Cancer | 05/11 | | | |
|
NCT00660582: FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor |
|
|
| Completed | 2 | 152 | Europe | Cetuximab (Erbitux), Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid | Per Pfeiffer, Odense University Hospital | Metastatic Colorectal Cancer | 05/11 | 02/13 | | |
|
NCT02142322: Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer |
|
|
| Completed | 2 | 52 | RoW | MODIFIED FOLFOX6 | Seoul National University Hospital | Advanced Gastric Cancer | 06/11 | 06/11 | | |
NCT00338039: Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients |
|
|
| Completed | 2 | 69 | US | Cetuximab, C225, Erbitux, IMC-C225, Gemcitabine, Gemzar, Gemcitabine Hydrochloride, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Radiotherapy, XRT | M.D. Anderson Cancer Center, Bristol-Myers Squibb | Pancreatic Cancer | 06/11 | 06/11 | | |
NCT00100841: Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer |
|
|
| Completed | 2 | 66 | US | cetuximab, C225, C225 monoclonal antibody, IMC-C225, MOAB C225, monoclonal antibody C225, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU | National Cancer Institute (NCI) | Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Stage IV Colon Cancer, Stage IV Rectal Cancer | 07/11 | 07/11 | | |
| Completed | 2 | 111 | Europe | FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium, zibotentan, laboratory biomarker analysis, pharmacogenomic studies | Cardiff University | Colorectal Cancer | 07/11 | 09/12 | | |
NCT00515216: Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors |
|
|
| Completed | 2 | 26 | US | 5-fluorouracil, 5-FU, Fluorouracil, Oxaliplatin, Eloxatin, Leucovorin, Wellcovorin, citrovorum factor, folinic acid, 5-formyl tetrahydrofolate | Vanderbilt University, University of Alabama at Birmingham, University of North Carolina, Washington University School of Medicine, National Cancer Institute (NCI) | Stomach Neoplasms, Esophageal Neoplasms | 08/11 | 11/13 | | |
| Terminated | 2 | 2 | US | FOLFOX, oxaliplatin, leucovorin, 5-fluorouracil, total mesorectal excision (TME), Total Mesorectal Excision | Beth Israel Medical Center, St. Luke's-Roosevelt Hospital Center | Rectal Neoplasms | 08/11 | 08/11 | | |
NCT01270438: Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | FOLFOX regimen, gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil | National Cancer Institute (NCI) | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer | 08/11 | 08/13 | | |
| Completed | 2 | 41 | Europe | Oxaliplatin, Sorafenib | Grupo Espanol Multidisciplinario del Cancer Digestivo | Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment) | 10/11 | 12/11 | | |
|
NCT00551759: Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer |
|
|
| Terminated | 2 | 22 | US | 5-Fluorouracil, 5-FU, Fluorouracil, Adrucil, Efudex, Oxaliplatin, Trans-l-diaminocyclohexane oxalatoplatinum, Cis-[oxalato (trans-I-1,2-diaminocyclohexane) platinum(II)], l-OHP, Eloxatin, Eloxatine, Dacplat, 5R96669, Cetuximab, Erbitux, C225, Docetaxel, Taxotere, RP 56976, Surgery, Radiotherapy | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) | Esophageal Cancer | 10/11 | 02/14 | | |
| Completed | 2 | 37 | Europe | FOLFOXIRI + Panitumumab | Gruppo Oncologico del Nord-Ovest | Metastatic Colo-rectal Cancer | 10/11 | | | |
|
NCT01454180 / 2011-001017-13: Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets |
|
|
| Completed | 2 | 31 | Europe | gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI., Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Apices Soluciones S.L., Grupo Hospital de Madrid | Advanced Pancreatic Carcinoma | 10/11 | 12/14 | | |
NCT00700570: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 45 | RoW | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 11/11 | 11/11 | | |
FOSCO, NCT00889343 / 2008-000803-26: Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer |
|
|
| Terminated | 2 | 101 | Europe | Sorafenib, Nexavar, Placebo, Oxaliplatin or Irinotecan, Leucovorin, 5-Fluorouracil | AIO-Studien-gGmbH | Colorectal Neoplasms | 11/11 | 12/12 | | |
| Terminated | 2 | 9 | Europe | Oxaliplatin, Capecitabine, Panitumumab, Oxaliplatin, Capecitabine | AIO-Studien-gGmbH, iOMEDICO AG | Colorectal Neoplasms | 11/11 | 03/12 | | |
NCT00585078: Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma |
|
|
| Completed | 2 | 40 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin | Beth Israel Deaconess Medical Center, Sanofi | Pancreatic Cancer | 12/11 | 12/11 | | |
NCT00642746: Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) |
|
|
| Terminated | 2 | 16 | US | Erlotinib, Tarceva, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan | OHSU Knight Cancer Institute, Genentech, Inc., OSI Pharmaceuticals | Metastatic Colorectal Cancer | 12/11 | 12/11 | | |
NCT00969033 / 2007-005675-34: CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin |
|
|
| Terminated | 2 | 8 | Europe | CS-1008, irinotecan, Camptosar | Daiichi Sankyo, Inc. | Metastatic Colorectal Cancer | 12/11 | 12/11 | | |
NCT00743678: Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis |
|
|
| Completed | 2 | 73 | RoW | FOLFOX6/cetuximab | Samsung Medical Center | Colorectal Cancer, Unresectable Liver Metastasis | 01/12 | 06/12 | | |
NCT01605305: Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer |
|
|
| Completed | 2 | 60 | RoW | FOLFOX6 | Fudan University | Esophageal Squamous Cell Carcinoma | 01/12 | 01/12 | | |
FLOT3, NCT00849615: Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction |
|
|
| Completed | 2 | 252 | Europe | Docetaxel, 5-Fluorouracil, Oxaliplatin, folinic acid | Krankenhaus Nordwest | Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction | 01/12 | 01/16 | | |
NCT01077739 / 2009-012090-36: A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin |
|
|
| Completed | 2 | 75 | Europe | fluorouracil (5FU), leucovorin, bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 01/12 | 01/12 | | |
NCT00177307: Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer |
|
|
| Completed | 2 | 40 | US | Bevacizumab, Capecitabine 2500 mg/m2/d in two divided doses, (May be 2000 or 3000 mg/m2/d after interim analysis) Days 1-8, every 2 weeks Until disease progression or unacceptable toxicity, Oxaliplatin 85 mg/m2 IV q 2 weekly Until disease progression, unacceptable toxicity,, or Grade 3 neuropathy or cumulative dose of 1200 mg/m2, Capecitabine, Oxaliplatin | University of Pittsburgh, Genentech, Inc. | Cancer | 02/12 | 02/12 | | |
| Withdrawn | 2 | 0 | Canada | irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab | Ottawa Hospital Research Institute, Hoffmann-La Roche, Sanofi | Metastatic Colorectal Cancer | 02/12 | 02/12 | | |
NCT00721916: Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 107 | Japan | SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin), mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin) | Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., LTD | Colorectal Cancer | 03/12 | 05/12 | | |
| Completed | 2 | 54 | US, Europe, RoW | Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid, 5-FU (mFOLFOX6) | Bayer | Colorectal Neoplasms | 03/12 | 06/14 | | |
|
NCT00601705: Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach |
|
|
| Completed | 2 | 61 | US | cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 03/12 | 01/15 | | |
| Completed | 2 | 150 | US | Docetaxel, Taxotere (docetaxel), cetuximab, ERBITUX (cetuximab), oxaliplatin, Eloxatin (oxaliplatin) | US Oncology Research, Eli Lilly and Company, Sanofi | Gastric Cancer Adenocarcinoma Metastatic | 04/12 | 04/12 | | |
|
| Completed | 2 | 150 | Europe | Gemox, Cetuximab | Gustave Roussy, Cancer Campus, Grand Paris, Merck Serono International SA | Advanced Biliary Cancer | 04/12 | 04/12 | | |
|
|
|
NCT00677144: Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer |
|
|
| Completed | 2 | 88 | RoW | OS (oxalipaltin+S-1), Eloxatin, TS-1, XELOX (oxalipaltin+capecitabine), Xeloda | Hallym University Medical Center, Sanofi | Colorectal Neoplasm | 04/12 | 04/12 | | |
NCT00982592: Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 124 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, placebo, PLCB, vismodegib, Erivedge, GDC-0449, Hedgehog antagonist GDC-0449, laboratory biomarker analysis | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer | 04/12 | 10/14 | | |
NCT01198548: High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 10 | US | leucovorin calcium, CF, CFR, LV, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, cholecalciferol, Calciol, Vitamin D3, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, pharmacological study, pharmacological studies | Roswell Park Cancer Institute, National Cancer Institute (NCI) | Stage IV Colon Cancer, Stage IV Rectal Cancer | 04/12 | 06/12 | | |
NCT00456599: Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer |
|
|
| Completed | 2 | 71 | US, Canada | gemcitabine, Gemzar, oxaliplatin, Eloxatin, Radiation, RT | University of Michigan Rogel Cancer Center, Sanofi, Johns Hopkins University, Princess Margaret Hospital, Canada, Ohio State University | Pancreatic Cancer | 05/12 | 01/13 | | |
NCT00707889 / 2007-007081-38: Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer |
|
|
| Completed | 2 | 159 | US, Canada, Europe, RoW | ABT-869, bevacizumab, oxaliplatin, mFOLFOX6 regimen, folinic acid, fluorouracil | AbbVie (prior sponsor, Abbott), Genentech, Inc. | Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 05/12 | 05/12 | | |
|
|
NCT00733616 / 2008-001825-32: Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status |
|
|
| Completed | 2 | 44 | Europe | DOX: Docetaxel, oxaliplatin, Capecitabine | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Sanofi, Hoffmann-La Roche | Gastric Cancer | 05/12 | 05/12 | | |
NCT00816543: Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma |
|
|
| Completed | 2 | 41 | RoW | DOCETAXEL, S-1, OXALIPLATIN | Sanofi | Gastric Cancer | 05/12 | 05/12 | | |
| Completed | 2 | 171 | US, Europe, RoW | CT-011, FOLFOX | Medivation, Inc. | Metastatic Colorectal Cancer | 05/12 | 03/13 | | |
|
| Withdrawn | 2 | 0 | Canada | OXALIPLATIN (SR96669), 5-FLUOROURACIL (5-FU), LEUCOVORIN (LV), BEVACIZUMAB | Sanofi | Colorectal Neoplasms | 05/12 | 05/12 | | |
NCT01127555: Salvage mFOLFOX in BTC After Failure of Gemcitabine |
|
|
| Completed | 2 | 30 | RoW | 5-fluorouracil, leucovorin, oxaliplatin, mFOLFOX | Chung-Ang University, Gyeongsang National University Hospital, Dong-A University Hospital, Samsung Medical Center | Unresectable Biliary Tract Cancer | 06/12 | 01/13 | | |
NCT00093379: Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer |
|
|
| Completed | 2 | 20 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Radiation Therapy (XRT), XRT, RT, Radiotherapy | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Anal Cancer | 07/12 | 07/12 | | |
NCT00767377: Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC |
|
|
| Completed | 2 | 163 | RoW | EOF5, treatment group | Fudan University | Gastric Cancer | 07/12 | 03/13 | | |
GEMOX-T, NCT00636883: Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer |
|
|
| Terminated | 2 | 9 | RoW | Gemcitabine, Oxaliplatin, Erlotinib | National Guard Health Affairs | Pancreatic Cancer | 07/12 | 07/12 | | |
NCT01175291: FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | MK-0646, oxaliplatin, leucovorin, 5-FU, Fluorouracil, bevacizumab, Placebo, 5-Fluorouracil | H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 07/12 | 07/12 | | |
NCT00755118: Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc |
|
|
| Terminated | 2 | 24 | Europe | Oxaliplatin, Eloxatin, LoHP, 5-Fluorouracil, 5-FU, Leucovorin, LV, Bevacizumab, Avastin, Irinotecan, CPT-11, Campto, Cetuximab, Erbitux | University Hospital of Crete | Colorectal Cancer | 08/12 | 08/12 | | |
NCT01364493: A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer |
|
|
| Completed | 2 | 51 | RoW | Trastuzumab+Capecitabine+Oxaliplatin, Herceptin, Xeloda, Eloxatin | Peking University | Gastric Cancer | 08/12 | 02/14 | | |
|
NCT01473303: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer |
|
|
| Withdrawn | 2 | 0 | US | ganitumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, placebo, questionnaire administration | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Pancreatic Cancer | 08/12 | | | |
NCT00536874: Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery |
|
|
| Completed | 2 | 39 | US | gemcitabine hydrochloride, oxaliplatin, protein expression analysis, proteomic profiling, diagnostic laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Pancreatic Cancer | 09/12 | 02/17 | | |
NCT01281761: Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) |
|
|
| Completed | 2 | 52 | RoW | cetuximab/irinotecan/simvastatin | Samsung Medical Center | Metastatic Colorectal Cancer | 09/12 | 12/12 | | |
|
|
NCT01157039: A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin |
|
|
| Withdrawn | 2 | 0 | Canada | Glutamine, L-glutamine | AHS Cancer Control Alberta, Cross Cancer Institute | Colorectal Carcinoma, Neoplasms, Colorectal, Colorectal Cancer, Colorectal Tumors, Metastasis | 09/12 | | | |
NCT00470184: Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer |
|
|
| Completed | 2 | 41 | US | capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy | Roswell Park Cancer Institute, National Comprehensive Cancer Network | Esophageal Cancer | 10/12 | | | |
| Completed | 2 | 60 | RoW | Chemotherapy | Chinese University of Hong Kong | Metastatic Colorectal Cancer | 10/12 | 10/12 | | |
|
NCT00217581: Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 39 | US | Bevacizumab, Avastin, Docetaxel, Taxotere, Oxaliplatin, Eloxatin | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 11/12 | 01/13 | | |
NCT01106066: Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1/RT vs. S-1/Oxaliplatin/RT |
|
|
| Terminated | 2 | 30 | RoW | Oxaliplatin, S-1, radiotherapy | Samsung Medical Center | Phase I: To Determine the Maximum Tolerated Dose (MTD), Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/Oxaliplatin | 11/12 | 11/12 | | |
NCT01531452: The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer |
|
|
| Completed | 2 | 43 | RoW | Oxaliplatin, eloxatin, s1, TS-1 | Chinese Academy of Medical Sciences | Stomach Neoplasms | 11/12 | 06/13 | | |
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
|
|
| Completed | 2 | 29 | Europe | Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L. | Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease | 11/12 | 12/14 | | |
NCT00250835: Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer |
|
|
| Terminated | 2 | 38 | US | Chemotherapy, Celecoxib, and Radiation, Celecoxib = Celebrex, Oxaliplatin = Eloxatin, Capecitabine = Xeloda | New Mexico Cancer Care Alliance | Rectal Cancer | 12/12 | 05/15 | | |
NCT01710592 / 2006-003332-29: A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer |
|
|
| Completed | 2 | 35 | Europe | Epirubicin, Oxaliplatin, Capecitabine, Docetaxel | Cancer Trials Ireland | Gastro Oesophageal Cancer | 12/12 | | | |
| Completed | 2 | 41 | RoW | External Beam Radiotherapy, Radiotherapy, RT, Oxaliplatin, Fluorouracil, Leucovorin, Surgical Resection | Trans Tasman Radiation Oncology Group, Trans Tasman Radiation Oncology Group (TROG) | Rectal Cancer | 12/12 | 12/12 | | |
